Wisconsin is currently home to 1355 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Milwaukee, Madison, Green Bay and Marshfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer
NCT05904080
Recruiting
This phase II trial tests how well nivolumab and ipilimumab immunotherapy with or without cabozantinib in treating patients with nasopharyngeal cancer that has come back (after a period of improvement) (recurrent), has spread from where it first started (primary site) to other places in the body (metastatic), or for which no treatment is currently available (incurable). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Marshfield Medical Center-EC Cancer Center, Eau Claire, Wisconsin
Conditions: Stage IV Nasopharyngeal Carcinoma AJCC v8, Nasopharyngeal Carcinoma
Register for Updates
A Study of DB-OTO, an Adeno-associated Virus (AAV) Based Gene Therapy, in Children/Infants With Hearing Loss Due to Otoferlin Mutations
NCT05788536
Recruiting
Regeneron is conducting a study of an investigational new drug called DB-OTO. DB-OTO is a gene therapy that is being developed to treat children who have hearing loss due to changes in the otoferlin gene. The purpose of this study is to: Learn about the safety of DB-OTO Determine how well DB-OTO is tolerated (does not cause ongoing discomfort) Evaluate the efficacy of DB-OTO (how well DB-OTO works)
Gender:
All
Ages:
17 years and below
Trial Updated:
06/19/2024
Locations: The Medical College of Wisconsin, Inc., Milwaukee, Wisconsin
Conditions: Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)
Register for Updates
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT05774951
Recruiting
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months.
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
06/19/2024
Locations: Research Site, Madison, Wisconsin
Conditions: Breast Cancer, Early Breast Cancer
Register for Updates
A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma (LITHOS)
NCT05755906
Recruiting
This is a 12-week study to evaluate the efficacy and safety of budesonide and formoterol fumarate metered dose inhaler relative to budesonide metered dose inhaler in adults and adolescents with inadequately controlled asthma.
Gender:
All
Ages:
Between 12 years and 80 years
Trial Updated:
06/19/2024
Locations: Research Site, Milwaukee, Wisconsin
Conditions: Asthma
Register for Updates
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
NCT05740566
Recruiting
The main objective is to compare the efficacy of tarlatamab with standard of care (SOC) on prolonging overall survival (OS).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: The Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Small Cell Lung Cancer (SCLC)
Register for Updates
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT05735483
Recruiting
The main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to <18 years of age with moderate-to-severe atopic dermatitis
Gender:
All
Ages:
Between 6 months and 18 years
Trial Updated:
06/19/2024
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Atopic Dermatitis, Eczema
Register for Updates
A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight
NCT05726227
Recruiting
This study will look at how well semaglutide helps children and teenagers losing weight. This will be tested by comparing the effect on body weight in children and teenagers taking semaglutide in comparison to placebo, a "dummy" medicine. In addition to taking the medicine, the child's parent and the child will have talks with study staff about healthy food choices, how to be more physically active and what your child can do to try to lose weight. The child will either get semaglutide or a "dumm... Read More
Gender:
All
Ages:
Between 6 years and 18 years
Trial Updated:
06/19/2024
Locations: Marshfield Clinic, Marshfield, Wisconsin
Conditions: Obesity
Register for Updates
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
NCT05723198
Recruiting
The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age. The study is divided into 4 periods, a 5-week Screening period, a 36-week Double-Blind Treatment Period, an approximately 2-year Long-term Extension Period, and a 4-week Post-treatment Follow-up period.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
06/19/2024
Locations: University of Wisconsin-Madison, Madison, Wisconsin
Conditions: Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical
Register for Updates
Antibiotic Cement Bead Pouch Versus Negative Pressure Wound Therapy
NCT05615844
Recruiting
The Beads vs Vac trial is a multi-centre randomized controlled trial of 312 participants with a severe open tibia fracture requiring multiple irrigation and debridement surgeries. Eligible participants will be randomized to receive either an antibiotic bead pouch or negative pressure wound therapy (NPWT) for their temporary open fracture wound management. Outcomes will be assessed at 6 weeks, 3 months, and 6 months post-surgery. The primary outcome will be a composite outcome to evaluate clinica... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Open tíbia Fracture
Register for Updates
A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)
NCT05592275
Recruiting
The main purpose of this study is to assess the efficacy and safety of LY3540378 in adults with worsening heart failure with preserved ejection fraction
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: University of Wisconsin Hospitals and Clinics, Madison, Wisconsin
Conditions: Heart Failure, Heart Failure With Preserved Ejection Fraction
Register for Updates
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT05559359
Recruiting
The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to <18 years of age with moderate-to-severe atopic dermatitis (AD).
Gender:
All
Ages:
Between 6 months and 17 years
Trial Updated:
06/19/2024
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Atopic Dermatitis, Eczema
Register for Updates
Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With AKT Mutations, A ComboMATCH Treatment Trial
NCT05554380
Recruiting
This phase II ComboMATCH treatment trial tests the usual treatment of chemotherapy (paclitaxel) plus ipatasertib in patients with solid tumor cancers that that cannot be removed by surgery (unresectable), has spread to nearby tissue or lymph nodes (locally advanced) or from where it first started (primary site) to other places in the body (metastatic), and has an AKT genetic change. Chemotherapy drugs, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killin... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Duluth Clinic Ashland, Ashland, Wisconsin
Conditions: Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Register for Updates